Can Hemophilia Patients Do IVF in Thailand? Thailand Third-Generation IVF Hemophilia Screening
Consultation Scenario: A Hemophilia Carrier’s Question
“My husband has mild hemophilia A, and we want a healthy baby. Domestic doctors recommend third-generation IVF, but the waiting time is long. I heard that Thailand can perform embryo screening for single-gene disorders. I wonder if we are eligible? What are the conditions? What is the process?” — This is a question raised by a 32-year-old woman during an overseas IVF consultation. Her husband has been genetically confirmed to have an F8 gene mutation, with factor VIII activity at about 15%. Both spouses have a normal karyotype, the woman’s AMH is 2.8 ng/ml, and her antral follicle count is 12. This case can answer many questions from hemophilia families about IVF in Thailand.
Hemophilia IVF in Thailand: Direct Answer
Yes, but with clear applicable conditions. Some reproductive centers in Thailand with PGT-M (Preimplantation Genetic Testing for Monogenic Disorders) qualifications can perform embryo-level genetic diagnosis for hemophilia A/B. The core prerequisites are:
- Both spouses clearly carry the pathogenic gene mutation site (genetic test report required);
- The woman’s ovarian reserve is adequate (AMH ≥ 1.5 ng/ml, AFC ≥ 8 is better);
- Normal karyotype, excluding other genetic abnormalities;
- Acceptance of potential loss from embryo biopsy (about 5% to 10% of embryos may stop developing due to biopsy damage).
It should be noted that PGT-M for hemophilia A/B in Thailand generally uses single-cell PCR combined with linkage analysis, with an accuracy rate >97%. However, not all Thai hospitals offer this technology; it is mainly concentrated in a few internationally certified centers in Bangkok, such as Jetanin, BNH, and Phyathai 3.
Why Can Hemophilia Be Blocked Through IVF?
Hemophilia A/B is an X-linked recessive genetic disorder. The pathogenic gene in male patients comes from the mother, while female carriers may pass it on to their offspring. During embryo genetic diagnosis, it is possible to distinguish between: normal embryos, carrier embryos, and affected embryos. Transplanting unaffected or carrier (non-symptomatic) embryos can block the inheritance.
In the Thai third-generation IVF process, embryos are cultured to the blastocyst stage on day 5-6, and 5-10 trophectoderm cells are biopsied. Gene amplification technology is then used to analyze whether the embryo carries the pathogenic mutation. The entire process does not damage the inner cell mass (which will develop into the fetus), theoretically having a limited impact on subsequent embryo development.
Doctor’s Perspective: What Situations Are Not Suitable for Thailand?
As an overseas coordinator, I often hear doctors emphasize the following criteria during communication:
- Woman’s age >42 years: Fewer eggs retrieved, drastically reduced chance of obtaining healthy embryos; cross-border operation is not recommended;
- Active coagulation disorder symptoms: For male hemophilia patients with factor activity <1% and no regular supplementation, there is a risk of bleeding during sperm or egg retrieval (requires prior consultation with a hematologist);
- Unclear gene locus: If only a clinical diagnosis exists without genetic verification, detection probes cannot be designed; Thai laboratories do not accept “clinically presumed” cases;
- Abnormal uterine environment: Such as severe intrauterine adhesions or adenomyosis affecting implantation; these need to be treated first.
A former clinical director of a Bangkok reproductive center once told me: “We welcome carrier families, but we must see a clear mutation site. If you don’t even have a genetic report, we will recommend completing genetic counseling in your home country first.”
Actual Process: From Consultation to Transfer
| Stage | Specific Content | Time Required |
|---|---|---|
| ① Preliminary Preparation | Complete genetic testing (both spouses + proband), karyotype, female ovarian assessment (AMH + antral follicle count), male semen analysis in home country | 1–2 months |
| ② Hospital Registration in Thailand | Submit genetic report, physical examination, infectious disease screening, sign informed consent | 3–5 days |
| ③ Ovarian Stimulation + Egg Retrieval | Start stimulation on day 2 of menstruation, about 10–12 days; male provides sperm on egg retrieval day | 15–18 days |
| ④ Embryo Culture + Biopsy | ICSI fertilization, culture to blastocyst on day 5/6, biopsy cells sent to genetic laboratory | 6–8 days |
| ⑤ PGT-M Testing + Results | Thai partner genetic lab performs single-cell PCR + linkage analysis, issues report | 2–3 weeks |
| ⑥ Frozen Embryo Transfer | Endometrial preparation (hormone replacement or natural cycle), transfer healthy embryo, blood test 12 days later | 18–25 days |
The entire cycle usually requires 2 trips abroad: first for ovarian stimulation, egg retrieval, and biopsy (about 20 days); second for endometrial preparation and transfer (about 12 days). The two trips are separated by 1–2 menstrual cycles.
Timeline Planning and Key Milestones
From the start of consultation to completion of transfer, the fastest time is 5–6 months. However, due to factors such as the genetic testing cycle, embryo biopsy queue, and timing of endometrial preparation, most families take 8–10 months. Special reminders:
- The genetic report must be completed before entering Thailand; Thai hospitals do not accept “testing in progress”;
- The woman’s AMH test is done by blood draw on day 2–3 of menstruation; semen analysis requires 3–5 days of abstinence;
- Passport validity must cover the entire cycle; a remaining validity of >1 year is recommended.
Factors Affecting Cost
The cost of hemophilia PGT-M IVF in Thailand generally ranges from 120,000 to 180,000 RMB. Differences mainly depend on:
- Hospital level: Top-tier private hospitals (e.g., Jetanin) charge higher, around 180,000 RMB;
- Number of biopsied embryos: Each additional embryo costs about 3,000–5,000 RMB extra;
- Whether a second biopsy is needed: Mosaic embryos require re-biopsy, with additional costs;
- Medication dosage: Poor ovarian response increases stimulation medication costs.
Special Situation Handling
If the Gene Locus is Rare or Unknown
Thai laboratories usually require a known mutation site. If only a clinical diagnosis (e.g., factor activity assay) exists without genotyping, primers cannot be designed. In such cases, whole-exome sequencing or targeted region capture must be done in the home country to find the pathogenic site. Some Thai centers may request sending the patient’s DNA sample for a pre-test to confirm feasibility before formally starting the cycle.
Male is a Hemophilia Patient
Male patients often have abnormal coagulation function, so bleeding risk must be assessed before sperm retrieval. It is recommended to consult a hematologist in advance to develop a peri-sperm retrieval replacement therapy plan. Thai hospitals generally require the male to start injecting clotting factor (e.g., factor VIII) 3 days before sperm retrieval to ensure safety.
Frequently Asked Questions
Q: Does being a hemophilia carrier increase the risk of miscarriage during IVF in Thailand?
A: PGT-M itself does not increase miscarriage. Miscarriage is more related to embryo chromosomal aneuploidy, maternal endometrium, immune factors, etc. However, hemophilia carriers are often older, so combining PGT-A (chromosomal screening) is recommended.
Q: After screening in Thailand, does the baby need to be tested for hemophilia after birth?
A: Even though PGT-M has an accuracy rate >97%, there is still a very low probability of misdiagnosis or missed mosaicism. Routine coagulation factor activity testing after birth is recommended for confirmation.
Q: I am a hemophilia carrier, my husband is normal. Can we choose the sex when doing IVF in Thailand?
A: Thailand allows sex selection, but for blocking X-linked genetic diseases, the main goal is to transplant embryos that are not affected, not simply to choose sex. Doctors will prioritize transplanting healthy male or healthy female embryos.
Practitioner Observations: Common Misconceptions and Details
In coordination work, I have found that many hemophilia families tend to overlook the following:
- Assuming that having a genetic report is enough, while ignoring the woman’s ovarian reserve — in reality, about 20% of carriers cannot enter the cycle due to low AMH;
- Believing that the success rate of IVF in Thailand is the same as at home — in fact, about 10%–15% of blastocysts stop developing due to biopsy damage, reducing the number of transferable embryos;
- Not reserving funds for embryo freezing renewal — if another transfer is needed, the annual fee for frozen embryos is about 3,000–5,000 RMB; forgetting to renew can lead to embryo disposal.
Risk Reminder
Going to Thailand for hemophilia IVF is not “foolproof.” Main risks include:
- No healthy embryos available for transfer after biopsy (especially when the woman is older and few eggs are retrieved);
- Cross-border medical care involves time zone communication, visa and policy changes (e.g., changes in Thai medical visa requirements);
- Some small clinics do not have genuine PGT-M capability; be wary of clinics that claim “third-generation IVF” but only perform chromosomal screening (PGT-A) rather than single-gene disease testing.
It is recommended to choose centers certified by the Thai Society of Reproductive Medicine with clear PGT-M case reports, and to request verification of laboratory qualifications and past hemophilia blocking case numbers in advance.
